Alzheimer's Drug Slows Cognitive Decline in Key Study

The pharmaceutical companies Biogen and Eisai said this week that a drug they are developing for Alzheimer's disease had slowed the rate of cognitive decline in a large late-stage clinical trial. From a report: The strong results boost the drug's chances of winning approval and offer renewed hope for a class of Alzheimer's drugs that have repeatedly failed or generated mixed results. The positive data also offer Biogen a second chance after the company's disastrous rollout of another Alzheimer's drug, Aduhelm. That medication won regulatory approval last year despite little evidence that it could slow cognitive decline, received only sharply limited coverage by Medicare and has proved to be a commercial failure. The results appear stronger for the new medication, lecanemab. Cognitive decline in the group of volunteers who received lecanemab was reduced by 27 percent compared with the group who received a placebo in the clinical trial, which enrolled nearly 1,800 participants with mild cognitive impairment or mild Alzheimer's disease, the companies said. The trial of lecanemab, which is administered via intravenous infusion, was the largest to date to test whether clearing the brain of plaques formed by the accumulation of a protein called amyloid could slow the progression of Alzheimer's disease. Aduhelm is designed to work in a similar way.

Read more of this story at Slashdot.